Haloperidol Forte Neuraxpharm (Haloperidol)

Haloperidol Forte Neuraxpharm is prescribed for several psychiatric conditions where dopamine D2 receptor blockade provides therapeutic benefit.

• Schizophrenia, including maintenance treatment of chronic symptoms.
• Acute psychotic episodes such as those associated with substance intoxication or withdrawal.
• Manic episodes of bipolar disorder, particularly when rapid symptom control is needed.
• Severe agitation or hostility that requires prompt calming.
• Tourette syndrome or other tic disorders when other therapies are insufficient.

Haloperidol Forte Neuraxpharm may cause a range of adverse effects; they are typically categorized by frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and reduced salivation.
• Constipation or gastrointestinal discomfort.
• Blurred vision, weight gain, or metabolic changes.

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Significant cardiac effects, including QT interval prolongation, arrhythmias, or severe hypotension.
• Severe depression, suicidal thoughts, or seizures.

When prescribing Haloperidol Forte Neuraxpharm, clinicians should consider several precautionary measures to minimize risk.

• Assess for a history of extrapyramidal disorders or Parkinsonian symptoms.
• Obtain baseline ECG and monitor QT interval, especially in patients with cardiac risk factors.
• Use the lowest effective dose in elderly patients due to increased fall and sedation risk.
• Exercise caution in pregnancy, lactation, and hepatic impairment; benefits must outweigh potential risks.
• Monitor for early signs of neuroleptic malignant syndrome, such as fever, muscle rigidity, or autonomic instability.
• Review concomitant use of other dopamine‑blocking agents to avoid additive effects.

Haloperidol Forte Neuraxpharm can interact with other medicines; understanding these interactions helps maintain safety and efficacy.

Avoid

• Other antipsychotics or dopamine antagonists that may increase extrapyramidal risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) that raise haloperidol plasma levels.
• Medications that prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, and some antipsychotics.
• Monoamine oxidase inhibitors (MAOIs) taken within 14 days, due to risk of severe hypotension or serotonin syndrome.

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce haloperidol effectiveness.
• Central nervous system depressants, including alcohol, benzodiazepines, and opioids, which can enhance sedation.
• Anticholinergic agents that may mask extrapyramidal symptoms.
• Antihypertensive drugs, as haloperidol may cause orthostatic hypotension.